Genmab granted Serono the exclusive worldwide rights to develop and commercialize a preclinical candidate HUMax-Tac useful for treating various T-cell mediated diseases including autoimmune disorders, inflammatory and hyperproliferative skin disorders and acute transplant rejection. The deal is worth up to US$40 M.